Dato for offentliggørelse af årsrapport for 2023 for ALK og webcast
January 31, 2024 03:44 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør årsrapport for 2023 torsdag den 8. februar 2024 om eftermiddagen. ALK afholder samme dag kl. 16.00 (CET) en telekonference for investorer og...
Release date of annual report 2023 for ALK and webcast
January 31, 2024 03:44 ET
|
ALK Abello
On Thursday, 8 February 2024 in the afternoon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors...
ALK’s europæiske registreringsansøgning for tabletvaccine mod husstøvmideallergi hos børn accepteret til vurdering
January 25, 2024 07:15 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) meddelte i dag, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn er accepteret til vurdering af de...
ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
January 25, 2024 07:15 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by...
ALK afslutter første del af fase 1-studie med peanuttablet
January 18, 2024 09:34 ET
|
ALK Abello
Studiet fortsætter nu i sin anden del, som forventes afsluttet senere i 2024.ALK indsender protokolændring for at udvide studiet til et fase 1-2 effektstudie. ALK (ALKB:DC / OMX: ALK B / AKBLF)...
ALK completes first part of phase 1 trial with peanut SLIT-tablet
January 18, 2024 09:34 ET
|
ALK Abello
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B /...
ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy
January 04, 2024 08:00 ET
|
ALK Abello
– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii – The Danish, pharmaceutical company ALK (ALKB:DC /...
ALK – Finanskalender for regnskabsåret 2024
December 20, 2023 04:45 ET
|
ALK Abello
Finanskalender 2024 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11. januar 2024: Stilleperiode8. februar 2024: Offentliggørelse af årsrapport 202314. marts 2024 kl. 16.00: Ordinær generalforsamling...
ALK – Financial calendar for the 2024 financial year
December 20, 2023 04:45 ET
|
ALK Abello
2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period 8 February 2024: Annual report 2023 14 March 2024 at 4.00 p.m.: Annual...
ALK udvider partnerskab med Torii i Japan
December 12, 2023 10:08 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) og selskabets japanske partner Torii Pharmaceutical Co., Ltd. (’Torii’) meddeler i dag, at de har udvidet samarbejdet og har indgået yderligere en licensaftale, der...